SCHEMBL7983126

SCHEMBL7983126

C[C@@]1(C(F)(F)F)OC(O)Cc2ccccc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 4/20 0.45
GRIN2B Q13224 2/20 0.44
KCNH2 Q12809 1/20 0.44
CYP3A4 P08684 2/20 0.37
MEN1 O00255 1/20 0.37
CYP2D6 P10635 1/20 0.37
ALOX15 P16050 1/20 0.37
CYP2C19 P33261 1/20 0.37
KMT2A Q03164 1/20 0.37
GRIN2D O15399 1/20 0.37
GRIN3B O60391 1/20 0.37
BCHE P06276 1/20 0.37
CHRM5 P08912 1/20 0.37
TSHR P16473 1/20 0.37
ALOX12 P18054 1/20 0.37
NFKB1 P19838 1/20 0.37
MAPK1 P28482 1/20 0.37
PRCP P42785 1/20 0.37
GRIN1 Q05586 1/20 0.37
GRIN2A Q12879 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7985550 1.00 SIGMAR1 (0.45) SIGMAR1GRIN2BKCNH2CYP3A4MEN1
SCHEMBL7982956 0.81 SIGMAR1 (0.55) SIGMAR1
SCHEMBL27379000 0.69 HTR2A (0.33) CYP3A4MAPK1
SCHEMBL8797042 0.67 CYP3A4 (0.47) GRIN2BCYP3A4MEN1CYP2D6ALOX15
SCHEMBL15731995 0.66 SIGMAR1 (0.42) SIGMAR1GRIN2BCYP3A4MEN1CYP2D6
Methane SCHEMBL28207565 0.66 CYP3A4 (0.46) GRIN2BCYP3A4MEN1CYP2D6ALOX15
SCHEMBL26331345 0.66 SIGMAR1 (0.42) SIGMAR1GRIN2BCYP3A4MEN1CYP2D6
SCHEMBL7982781 0.66 PDK2 (0.34)
SCHEMBL28302686 0.65 CYP3A4 (0.41) SIGMAR1GRIN2BCYP3A4MEN1CYP2D6
SCHEMBL28145473 0.63 CYP3A4 (0.43) SIGMAR1GRIN2BCYP3A4MEN1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6239147-B1 TO TREAT CNS, GASTROINTESTINAL AND OTHER DISORDERS. SUBSTANCE P ANTAGONISTS HAVING IMPROVED ACTIVITY AND FEWER SIDE EFFECTS, TREATMENT OF EMESIS INDUCED BY ANTINEOPLASTIC AGENTS, ISOCHROMAN RING PFIZER INC 2001-05-29 US disclosed